Armed with a brand-new patent, Roche demands royalties on Lilly’s psoriasis drug Taltz
2018-07-05
Scroll to see more.
 

IP News

Home > IP News

Armed with a brand-new patent, Roche demands royalties on Lilly’s psoriasis drug Taltz

Armed with a brand-new patent, Roche demands royalties on Lilly’s psoriasis drug Taltz

2018-07-05

Here’s a patent gambit for you: Roche’s Genentech unit sued Eli Lilly for infringement Tuesday, claiming the Indianapolis drugmaker’s psoriasis drug Taltz steps on one of its patents.

Thing is, Genentech just won that patent this week.

Taltz has been on the market since 2016—long enough to build up to $486 million in U.S. sales last year, despite heavy competition in its field from Novartis’ first-to-market Cosentyx and other newcomers. But Genentech alleges that the drug, which works by inhibiting the immunology pathway IL-17, infringes its own brand-new patent that covers biological drugs that target that specific pathway.

source: https://www.fiercepharma.com/lilly-s-taltz-infringes-new-genentech-patent-lawsuit-says

 

Privacy Statement
Our company is deeply committed to protecting the privacy and personal information of our users. In accordance with our website's privacy policy, we promise to safeguard user personal information from infringement. If you have any questions regarding our privacy policy, please feel free to contact us via email or phone. We are more than happy to assist you.